These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Toulis KA; Anastasilakis AD; Polyzos SA; Makras P Hormones (Athens); 2011; 10(3):174-95. PubMed ID: 22001129 [TBL] [Abstract][Full Text] [Related]
6. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Marie PJ; Kassem M Eur J Endocrinol; 2011 Jul; 165(1):1-10. PubMed ID: 21543379 [TBL] [Abstract][Full Text] [Related]
7. [Update and perspectives of anabolic therapies for osteoporosis]. Endo I; Matsumoto T Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299 [TBL] [Abstract][Full Text] [Related]
8. Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis. Widler L Future Med Chem; 2011 Apr; 3(5):535-47. PubMed ID: 21526895 [TBL] [Abstract][Full Text] [Related]
9. [Hormones and osteoporosis update. Mechanisms of anabolic and catabolic effects of PTH on bone]. Kobayashi T Clin Calcium; 2009 Jul; 19(7):911-8. PubMed ID: 19567985 [TBL] [Abstract][Full Text] [Related]
10. Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments. Dede AD; Makras P; Anastasilakis AD Expert Opin Investig Drugs; 2017 Oct; 26(10):1137-1144. PubMed ID: 28836858 [TBL] [Abstract][Full Text] [Related]
11. Potential new drug targets for osteoporosis. Deal C Nat Clin Pract Rheumatol; 2009 Jan; 5(1):20-7. PubMed ID: 19098925 [TBL] [Abstract][Full Text] [Related]
12. [Anabolic therapy of osteoporosis]. Okopień B; Krysiak R; Labuzek K; Herman ZS Pol Merkur Lekarski; 2005 Jul; 19(109):118-21. PubMed ID: 16194044 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in skeletal anabolic therapies. Martin TJ; Quinn JM; Gillespie MT; Ng KW; Karsdal MA; Sims NA Ann N Y Acad Sci; 2006 Apr; 1068():458-70. PubMed ID: 16831943 [TBL] [Abstract][Full Text] [Related]
15. Novel and potent calcium-sensing receptor antagonists: discovery of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide monotosylate (TAK-075) as an orally active bone anabolic agent. Yoshida M; Mori A; Morimoto S; Kotani E; Oka M; Notoya K; Makino H; Ono M; Shirasaki M; Tada N; Fujita H; Ban J; Ikeda Y; Kawamoto T; Goto M; Kimura H; Baba A; Yasuma T Bioorg Med Chem; 2011 Mar; 19(6):1881-94. PubMed ID: 21353570 [TBL] [Abstract][Full Text] [Related]
16. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis. Garcés C; García LE Maturitas; 2006 Apr; 54(1):47-54. PubMed ID: 16257150 [TBL] [Abstract][Full Text] [Related]
17. Update in new anabolic therapies for osteoporosis. Canalis E J Clin Endocrinol Metab; 2010 Apr; 95(4):1496-504. PubMed ID: 20375217 [TBL] [Abstract][Full Text] [Related]
18. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. Nemeth EF IDrugs; 2008 Nov; 11(11):827-40. PubMed ID: 18988128 [TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone as an anabolic therapy for women and men. Bilezikian JP; Rubin MR; Finkelstein JS J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201 [TBL] [Abstract][Full Text] [Related]
20. A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. Chan A; van Bezooijen RL; Löwik CW Curr Opin Investig Drugs; 2007 Apr; 8(4):293-8. PubMed ID: 17458178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]